Thomas Burmeister

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text

Medicine, Hematology, Oncology +16

The MLL recombinome of acute leukemias in 2017

Claus Meyer, Thomas Burmeister, Daniela Gröger et al. · Leukemia · 2017 · 686 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

The MLL recombinome of acute leukemias in 2013

Claus Meyer, Jörg Hofmann, Thomas Burmeister et al. · Leukemia · 2013 · 507 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Blood · 2012 · 469 citations · Full text

Medicine, Hematology, Oncology +15

New insights to the MLL recombinome of acute leukemias

Claus Meyer, Eric Kowarz, Jörg Hofmann et al. · Leukemia · 2009 · 411 citations

Life Sciences, Molecular Biology, Molecular Genetics +11